Intravenous immune globulin for multiple sclerosis.
This article is an executive summary of the Blue Cross Blue Shield Technology Evaluation Center (TEC) Assessment "Intravenous Immune Globulin for Multiple Sclerosis" Volume 9, No. 26, 1994. The complete assessment, which includes background information, methods, formulation of the assessment, review of evidence, conclusions, and references are available to Blue Cross Blue Shield TEC Program subscribers only.  For subscription information, contact the program at (312) 440-6080.
D054598:Blue Cross Blue Shield Insurance Plans; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care; D013673:Technology Assessment, Biomedical; D014481:United States; D014486:United States Food and Drug Administration